Abstract
Exercise confers protection against obesity, type 2 diabetes and other cardiometabolic diseases1–5. However, the molecular and cellular mechanisms that mediate the metabolic benefits of physical activity remain unclear6. Here we show that exercise stimulates the production of N-lactoyl-phenylalanine (Lac-Phe), a blood-borne signalling metabolite that suppresses feeding and obesity. The biosynthesis of Lac-Phe from lactate and phenylalanine occurs in CNDP2+ cells, including macrophages, monocytes and other immune and epithelial cells localized to diverse organs. In diet-induced obese mice, pharmacological-mediated increases in Lac-Phe reduces food intake without affecting movement or energy expenditure. Chronic administration of Lac-Phe decreases adiposity and body weight and improves glucose homeostasis. Conversely, genetic ablation of Lac-Phe biosynthesis in mice increases food intake and obesity following exercise training. Last, large activity-inducible increases in circulating Lac-Phe are also observed in humans and racehorses, establishing this metabolite as a molecular effector associated with physical activity across multiple activity modalities and mammalian species. These data define a conserved exercise-inducible metabolite that controls food intake and influences systemic energy balance.
| Original language | English |
|---|---|
| Pages (from-to) | 785-790 |
| Number of pages | 6 |
| Journal | Nature |
| Volume | 606 |
| Issue number | 7915 |
| Early online date | 15 Jun 2022 |
| DOIs | |
| Publication status | Published - 23 Jun 2022 |
Bibliographical note
Funding Information:We thank members of the Long, Xu, Snyder, Richter and Svensson laboratories, and L. Sylow for helpful discussions. This work was supported by the NIH (DK124265 and DK130541 to J.Z.L.; DK113954, DK115761, DK117281 and DK120858 to Y.X.; GM113854 to V.L.L.; and AR072695 to K.v.d.W), the Ono Pharma Foundation (research grant to J.Z.L.), BASF (research grant to J.Z.L.), the USDA (51000-064-01S to Y.X.), the American Heart Association (20POST35120600 to Y.H.), the Novo Nordisk Foundation (NNF17OC0027274 and NNF18OC00334072 to E.A.R.) and PXE International (research grant to K.v.d.W.).
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature Limited.
Keywords
- Adiposity/drug effects
- Animals
- Body Weight/drug effects
- Diabetes Mellitus, Type 2
- Disease Models, Animal
- Eating/physiology
- Energy Metabolism
- Feeding Behavior/physiology
- Glucose/metabolism
- Lactic Acid/metabolism
- Mice
- Obesity/metabolism
- Phenylalanine/administration & dosage
- Physical Conditioning, Animal/physiology
ASJC Scopus subject areas
- General